2016 EHA Annual Meeting Highlights in HL

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 06, 2016
Expiration Date: July 06, 2017

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The European Hematology Association (EHA) 2016 Annual Meeting highlights for Hodgkin lymphoma covers the most exciting and clinically relevant data presented at the conference. A group of expert faculty, including Dr. Peter Borchmann, Dr. Paul Bröckelmann, Dr. Astrid Pavlovsky, and Dr. Anas Younes, provide overviews of data spanning topics such as, immuno-oncology, PET-adapted therapy, real-world use of brentuximab vedotin and data from the German Hodgkin Study Group, while sharing insights into the impact of these data on clinical practice.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in managing Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify the most clinically relevant and potentially impactful Hodgkin lymphoma presentations from the European Hematology Association 2016 Annual Meeting
  • Describe the clinical impact of emerging data on treatment strategies and novel therapies for the treatment of patients with Hodgkin lymphoma


Updates from the German Hodgkin Study Group (GHSG) – Peter Borchmann, MD

Real-World Data on Brentuximab Vedotin in Hodgkin Lymphoma – Paul Bröckelmann, MD

PET-Adapted Therapy in Hodgkin Lymphoma
– Astrid Pavlovsky, MD

Immuno-oncology in Hodgkin Lymphoma
– Anas Younes, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 6, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Peter Borchmann, MD
Assistant Medical Director
Department of Hematology/Oncology
University Hospital of Cologne
Cologne, Germany

Dr. Peter Borchmann is Assistant Medical Director in the Department of Hematology/Oncology at the University Hospital of Cologne where he is Head of the Lymphoma Program. He is also Study Secretary of the German Hodgkin Study Group (GHSG) and responsible for development and investigator initiated clinical studies in Hodgkin lymphoma (HL). Dr. Borchmann’s scientific focus within the GHSG is to optimize the treatment of advanced stage HL patients and elderly patients. He is also the leader of the working group “Survivorship” (http://www.ghsg.org).

Paul Bröckelmann, MD
German Hodgkin Study Group (GHSG)
Department I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Dr. Paul Bröckelmann received his medical training at the University of Cologne, Germany. He completed internships in surgery at Universidad de Buenos Aires – Argentina, Internal Medicine at University Hospital of Cologne – Germany, Internal Medicine at Brighton Sussex Medical School – England, and Psychiatry at University Hospital of Cologne. In addition, he completed the Master Class of the European Hematology Association (EHA). Dr. Bröckelmann is at the Department of Internal Medicine, University Hospital of Cologne, and a trial physician with the German Hodgkin Study Group.

Astrid Pavlovsky, MD
Medical Director
Pavlovsky Center for Hematology
Buenos Aires, Argentina

Dr. Astrid Pavlovsky received her medical degree from Universidad del Salvador. In addition, she holds a degree in hematology from Argentine Society of Hematology, University of Buenos Aires, and a degree in internal medicine from Hospital Italiano de Buenos Aires, where she also completed a residency program in general internal medicine. She is Medical Director at the Pavlovsky Center for Hematology, Buenos Aires, Argentina.

Dr. Pavlovsky, a specialist in hematology, is on the Ethics Committee, FUNDALEU; the Experts Committee, Iberoamerican Society of Scientific Information (SIIC); chairman of Hodgkin lymphoma clinical trial (GATLA Protocol 08-LH-05); secretary of GATLA, a cooperative group for the treatment of onco-hematological malignancies, and is Principal Investigator of the Alcyone Study.

Anas Younes, MD
Chief, Lymphoma Service
Division of Hematologic Oncology, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Anas Younes received his medical degree from the University of Damascus School of Medicine in Syria. He completed residencies in pathology at the Medical College of Ohio and in internal medicine at SUNY Downstate Medical Center, as well as a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Younes is Chief of Memorial Sloan Kettering's Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma.

Dr. Younes, a board-certified medical oncologist, serves on the Scientific Advisory Board of the Lymphoma Research Foundation, and is a past member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and led the National Cancer Institute–funded SPORE (Specialized Programs of Research Excellence) in lymphoma.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-16-101-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 16-101-031


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Drs. Peter Borchmann and Astrid Pavlovsky have disclosed no relevant financial relationships.

Dr. Paul Bröckelmann has received honoraria as a consultant from Takeda Oncology.

Dr. Anas Younes has received honoraria as a consultant from Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Janssen Pharmaceuticals, Inc., Sanofi, Seattle Genetics, Inc., Merck & Co., Inc., and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb, Curis, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., and Novartis AG.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. Borchmann, Bröckelmann, Pavlovsky, and Younes have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Borchmann, Bröckelmann, Pavlovsky, and Younes have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.